A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.
Chemical ID:
MESH:C070081
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Estradiol inhibits the reaction [Fulvestrant results in decreased expression of ESR2 mRNA alternative form], Fulvestrant inhibits the reaction [[[INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] co-treated with bisphenol A] results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [dioscin results in increased expression of ESR2 protein], Fulvestrant inhibits the reaction [ESR2 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]], Fulvestrant inhibits the reaction [Estrogens results in increased activity of ESR2 protein polymorphism], Fulvestrant inhibits the reaction [sodium arsenite results in increased expression of ESR2 mRNA], Fulvestrant inhibits the reaction [sodium arsenite results in increased expression of ESR2 protein]
fulvestrant binds to and results in decreased activity of ESR2 protein, fulvestrant inhibits the reaction [16 alpha-iodoestradiol binds to ESR2 protein], fulvestrant inhibits the reaction [[Ethinyl Estradiol co-treated with Triclosan] results in decreased expression of ESR2 mRNA], fulvestrant inhibits the reaction [naringin results in increased expression of ESR2 mRNA]
6-OH-BDE-47 promotes the reaction [Fulvestrant results in decreased expression of ESR2 protein], Fulvestrant binds to and results in decreased activity of ESR2 protein, Fulvestrant inhibits the reaction [2, 2', 4, 4'-tetrabromodiphenyl ether results in increased expression of ESR2 protein], Fulvestrant inhibits the reaction [3, 3', 4, 5'-tetrahydroxystilbene results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [[Estradiol co-treated with ESR2 protein] results in increased expression of NOS3 mRNA], Fulvestrant inhibits the reaction [Androstane-3, 17-diol analog binds to and results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [Androstane-3, 17-diol binds to and results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]], Fulvestrant inhibits the reaction [bisphenol A results in increased expression of ESR2 mRNA], Fulvestrant inhibits the reaction [Cadmium Chloride results in increased expression of ESR2 protein], Fulvestrant inhibits the reaction [Diarylheptanoids results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [diarylpropionitrile results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [Dihydrotestosterone results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [Dihydrotestosterone results in increased localization of ESR2 protein], Fulvestrant inhibits the reaction [Estradiol results in decreased expression of ESR2 mRNA], Fulvestrant inhibits the reaction [Estradiol results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA], Fulvestrant inhibits the reaction [Estradiol results in increased expression of ESR2 protein], Fulvestrant inhibits the reaction [Estradiol results in increased localization of ESR2 protein], Fulvestrant inhibits the reaction [Genistein results in increased expression of ESR2 protein], Fulvestrant inhibits the reaction [methoxyacetic acid promotes the reaction [Estradiol results in increased activity of ESR2 protein]], Fulvestrant inhibits the reaction [Plant Preparations results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [prochloraz results in decreased expression of ESR2 mRNA], Fulvestrant inhibits the reaction [Resveratrol results in increased activity of ESR2 protein], Fulvestrant inhibits the reaction [rhapontigenin analog results in increased activity of ESR2 protein], Fulvestrant promotes the reaction [5-OH-BDE-47 results in decreased expression of ESR2 protein], Fulvestrant promotes the reaction [6-OH-BDE-47 affects the expression of ESR2 protein], Fulvestrant promotes the reaction [ESR1 protein binds to ESR2 protein]
